Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control regimen Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Dexcom G6, Contour NextOne; Device
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Holladay, Utah • Murray, Utah • Salt Lake City, Utah

Conditions: Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions: Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance; Device
Lead sponsor: Florida State University; Other
Eligibility: 60 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: End Stage Renal Failure With Renal Transplant
Interventions: Tacrolimus with MMF, Group 2: Tacrolimus with Everolimus.; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Tibial Fractures, Pain
Interventions: 600 mg Ibuprofen; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Cambridge, Massachusetts + 9 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GW873140; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 52
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 43 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Escondido, California • Atlanta, Georgia + 1 more

Conditions: Uncontrolled Hypertension
Interventions: CIN-107, Placebo; Drug
Lead sponsor: CinCor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more

Conditions: Chorea Associated With Huntington Disease
Interventions: SD-809; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more

Conditions: Asthma
Interventions: MEMP1972A, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 51
States / cities: Birmingham, Alabama • Bakersfield, California • Costa Mesa, California + 46 more

Conditions: Thoracic, Pulmonary Disease
Interventions: Gabapentin, Placebo; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C, Chronic
Interventions: Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 85
States / cities: Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Conditions: Tobacco Use Disorder
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hidradenitis Suppurativa (HS)
Interventions: ORKA-002, Placebo; Drug · Other
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more

Conditions: Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions: Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy; Drug · Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 72
States / cities: Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more

Conditions: Abortion, Medical
Interventions: Misoprostol-only medication abortion regimen, Combined regimen; Drug
Lead sponsor: Ibis Reproductive Health; Other
Eligibility: 14 Years and older · Female only
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV-1
Interventions: D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more

Conditions: Type 1 Diabetes Mellitus
Interventions: teplizumab, Placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 34
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 30 more

Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: Olaparib, Physician's choice chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 42
States / cities: San Diego, California • Santa Rosa, California • Whittier, California + 35 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin Glargine, Insulin Aspart, Insulin Lispro; Drug
Lead sponsor: University of Miami; Other
Eligibility: 65 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Multiple Sclerosis, Healthy
Interventions: Blood draw; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Hypersomnia
Interventions: JZP-258, Placebo Oral Solution; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more

Conditions: HIV Infections, Lipodystrophy, Wasting Disease
Interventions: Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more

Conditions: Alzheimer's Disease
Interventions: CHF 5074 1x, CHF 5074 2x, CHF 5074 3x, Placebo; Drug
Lead sponsor: CERESPIR; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: St. Petersburg, Florida • Eatontown, New Jersey • Monroe Twp, New Jersey + 2 more

Conditions: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
Interventions: BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more

Search by objective public record fields.

CGM - Reimagine Primary Care

IMST for Dementia Risk Reduction

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles

A Study of CIN-107 in Patients With Uncontrolled Hypertension

Alternatives for Reducing Chorea in Huntington Disease

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Effect of Ramelteon on Smoking Abstinence

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

The Misoprostol-Only Regimen Evidence Study

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Simplified Insulin Regimen for the Elderly

COVID-19 Vaccine Response in Treated MS Patients

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)